SynthesisFrontiers in oncology2023
Clinical significance of the advanced lung cancer inflammation index in gastrointestinal cancer patients: a systematic review and meta-analysis.
Synthesis in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- Gustave Roussy Immune (GRIm) score as a novel prognostic biomarker for gastrointestinal cancers: a meta-analysis of sixteen studies.World journal of surgical oncology · 2026Pooled it
- Clinical significance of the pretreatment C-reactive protein-albumin-lymphocyte (CALLY) index in colorectal cancer patients: a meta-analysis.BMC cancer · 2026Pooled it
- Prognostic value of the pretreatment pan-immune-inflammation value in patients with head and neck squamous cell carcinoma: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Prognostic value of the pretreatment Naples prognostic score in gastrointestinal cancer patients: an updated meta-analysis with 28 studies.Systematic reviews · 2025Pooled it
- Prognostic significance of the pretreatment pan-immune-inflammation value in colorectal cancer patients: an updated meta-analysis.Frontiers in oncology · 2025Pooled it
- Pooled it
- Prognostic significance of the pretreatment pan-immune-inflammation value in cancer patients: an updated meta-analysis of 30 studies.Frontiers in nutrition · 2023Pooled it
- Predicting intestinal ischemia in mechanical intestinal obstruction: the role of the C-reactive protein-albumin-lymphocyte index.Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES · 2026Article
- The preoperative LDL-C to HDL-C ratio evaluates prognosis in hepatocellular carcinoma patients after hepatectomy.Discover oncology · 2026Article
- Development and Validation of a Nomogram Based on Advanced Lung Cancer Inflammation Index for Predicting Overall Survival in Non-Surgical Esophageal Squamous Cell Carcinoma.Journal of inflammation research · 2026Article
- Article
- A cross-sectional study examining the relationship between the advanced lung cancer inflammation index and prostate cancer.Journal of health, population, and nutrition · 2025Article
- The role of the advanced lung cancer inflammation index (ALI) in the risk of liver fibrosis and mortality among US adult MAFLD patients: a cross-sectional study of NHANES 1999-2018.BMC gastroenterology · 2025Article
- Predictive Efficacy of the Advanced Lung Cancer Inflammation Index in Hepatocellular Carcinoma After Hepatectomy.Journal of inflammation research · 2024Article
- Advanced lung cancer inflammation index predicts overall survival of hepatocellular carcinoma after hepatectomy.Frontiers in oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The advanced lung cancer inflammation index (ALI) has been identified as a scientific and clinical priority in multiple malignancies. The aim of this study is to investigate the value of the ALI before treatment in evaluating postoperative complications (POCs) and survival outcomes in patients with gastrointestinal (GI) cancer. Methods: Electronic databases including PubMed, Embase and Web of Science were comprehensively reviewed up to June 2022. The endpoints were POCs and survival outcomes. Subgroup analyses and sensitivity analyses were also performed. Results: Eleven studies including 4417 participants were included. A significant heterogeneity in the ALI cut-off value among studies was observed. Patients in the low ALI group showed increased incidence of POCs (OR=2.02; 95%CI:1.60-2.57; P<0.001; I Conclusion: Based on existing evidence, the ALI could act as a valuable predictor of POCs and long-term outcomes in patients with GI cancer. However, the heterogeneity in the ALI cut-off value among studies should be considered when interpreting these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.